<DOC>
	<DOC>NCT00076635</DOC>
	<brief_summary>Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.</brief_summary>
	<brief_title>An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF</brief_title>
	<detailed_description>Open-label therapy will be administered subcutaneously. Patients enrolled will continue to receive Interferon gamma-1b therapy three times per week and will be evaluated at 6-week intervals. Patients not taking Interferon gamma-1b at enrollment will re-initiate therapy with subcutaneous Interferon gamma-1b under a dose-escalation scheme, reaching full dose after 2 weeks.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion criteria: Enrollment in Protocol GIPF 002 Part B or GIPF004 Completion of the End of Treatment Visit in Protocol GIPF002 Part B or the Study Completion Visit in GIPF004 Able to understand and sign a written informed consent form and comply with the requirements of the study Exclusion criteria: pregnancy or lactation lack of adherence to either GIPF002 or GIPF004 study protocols and treatment regimens if Principal Investigator deems patient is unsuitable for study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Lung</keyword>
	<keyword>Actimmune</keyword>
	<keyword>Interferon</keyword>
	<keyword>Gamma</keyword>
	<keyword>InterMune</keyword>
</DOC>